Research Library › Peptide Fragments
KPV is a tripeptide made of lysine, proline and valine, identical to the last three amino acids (positions 11–13) of the 13-amino-acid hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It was patented by James M. Lipton of the University of Texas Southwestern Medical Center, with a 1984 priority date. As of 22 Oct 2026 KPV is not FDA-approved, and the FDA had not acted on a July 2026 advisory committee vote about compounding it.
Key facts
| Type | Tripeptide (3 amino acids) |
|---|---|
| Sequence | Lys-Pro-Val (KPV) |
| Derived from | C-terminal residues 11–13 of alpha-MSH, unmodified |
| First described | 1984 (rabbit study; patent priority date) |
| Developed by | James M. Lipton, University of Texas Southwestern Medical Center, Dallas |
| Designed target | Molecular targets unknown per FDA; preclinical reports propose uptake via the PepT1 transporter |
| Regulatory status (Oct 2026) | Not FDA-approved; PCAC voted 8–6–1 in July 2026; no final FDA decision |
Who developed it
KPV was patented by James M. Lipton of the University of Texas Southwestern Medical Center in Dallas, claiming a 1984 priority date [1]. That same year, Lipton and D.B. Richards published a study of the tripeptide in rabbits [2]. Lipton later collaborated with A. Catania’s group in Milan on the broader alpha-MSH family [3].
Work on the intestine came later from a German team including Torsten Kucharzik at the University of Münster, which studied KPV in mouse models of inflammatory bowel disease in 2008 [4].
What it was designed to target
Alpha-MSH is a 13-amino-acid peptide hormone best known for its role in skin pigmentation. KPV consists only of its final three residues, lysine, proline and valine, with no chemical changes [1, 5].
Because KPV lacks the core sequence alpha-MSH uses to bind melanocortin receptors, it is not expected to act on those receptors in the way the parent hormone does [5]. Preclinical reports have proposed that intestinal cells take it up through a peptide transporter called PepT1. In its 2026 briefing document the FDA described KPV’s molecular targets as unknown [6].
Why it was created
Lipton was studying how alpha-MSH participates in the body’s regulation of fever. His group proposed that the hormone’s short C-terminal tail carried what they called its antipyretic message, and the patent described compositions built on the tripeptide for further research in fever and inflammation [1, 7].
Later work extended the investigation to preclinical models of skin and intestinal inflammation [4, 7]. The FDA’s 2026 review found no information on KPV given to humans and no standard toxicity studies [6].
Research timeline
- 1984: Rabbit study published; patent priority date [1, 2]
- 1989: Studied in a mouse model of skin inflammation [7]
- 1992: US Patent 5,157,023 granted [1]
- 2008: Mouse studies in models of inflammatory bowel disease [4]
- July 2026: FDA advisory committee votes 8–6, with one abstention [8]
Regulatory status as of October 2026
KPV is not approved as a drug by the FDA or any other regulator. It had appeared on the FDA’s list of bulk substances that may present significant safety risks in compounding [9].
Wells Pharmacy Network originally nominated KPV for compounding and later withdrew its nomination, but the FDA reviewed both the free base and acetate forms on its own initiative. FDA staff proposed not adding KPV to the compounding list [6]. On 23 July 2026 the Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend allowing it [8, 10]. The vote is advisory; as of 22 Oct 2026 no final FDA decision had been made [11]. An FDA interim access policy covering certain peptides was sent for White House review on 14 Oct 2026 [12].
KPV is not named on the 2026 WADA Prohibited List; its catch-all section S0 covers substances with no approval for human therapeutic use [13].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What is KPV?
KPV is a three-amino-acid peptide (lysine-proline-valine) identical to the final three residues of the hormone alpha-MSH [1, 5].
Who discovered KPV?
James M. Lipton of the University of Texas Southwestern Medical Center patented KPV, with a 1984 priority date, after studying alpha-MSH’s role in fever regulation [1, 2].
Sources
- Lipton JM. Antipyretic and anti-inflammatory Lys Pro Val compositions and method of use. US Patent 5,157,023 (priority 21 Aug 1984; granted 20 Oct 1992). Link
- Richards DB, Lipton JM. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides. 1984. PMID 6333677. Link
- Delgado Hernàndez R, Demitri MT, Carlin A, Meazza C, Villa P, Ghezzi P, Lipton JM, Catania A. Inhibition of systemic inflammation by central action of the neuropeptide alpha-melanocyte-stimulating hormone. Neuroimmunomodulation. 1999;6(3):187–192. Link
- Kannengiesser K, Maaser C, Heidemann J, et al., Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–331. doi:10.1002/ibd.20334. Link
- Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-MSH related peptides beyond the pharmacophore. In: Catania A, ed. Melanocortins. Adv Exp Med Biol. 2010;681:107–116. Link
- U.S. FDA. KPV-related bulk drug substances (KPV free base, KPV acetate): briefing document, Pharmacy Compounding Advisory Committee, 23 Jul 2026. Link
- Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282–2284. Link
- Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (KPV and cathelicidin LL-37 entries). Content current as of 22 Apr 2026. Link
- Regulatory Focus (RAPS). FDA advisory committee backs two controversial peptides. 23 Jul 2026. Link
- Buchanan Ingersoll & Rooney. FDA advisory committee voted yes on six peptides. Now what? 18 Aug 2026. Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
